You are here

Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44CA257457-01A1
Agency Tracking Number: R44CA257457
Amount: $1,629,519.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA20-260
Timeline
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-05-01
Award End Date (Contract End Date): 2023-04-30
Small Business Information
675 US HWY 1, STE 127
North Brunswick, NJ 08902-3378
United States
DUNS: 080232998
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 THOMAS VILLANI
 (800) 615-8474
 tom.villani@visikol.com
Business Contact
 NICK CRIDER
Phone: (603) 490-3256
Email: nick.crider@visikol.com
Research Institution
N/A
Abstract

Summary
The objective of this Phase II project is to improve outcomes and survival for patients with melanoma by
reducing the number of false negative sentinel lymph node biopsies wherein metastatic disease is missed
through conventional tissue processing and histological characterization. It is estimated that 4,200 patients are
misdiagnosed in this manner in the US per year which results in more conservative treatment regimens for
these patients than is required to effectively treat their disease. The outcome of patients not receiving the
proper treatment regimen is that they experience a three-year reduction in ten-year survival which on a quality
adjusted life year basis translates into a $1.2 billion economic loss. To address this problem, we have
developed a three-dimensional tissue imaging and digital analysis approach which allows for the complete
characterization of sentinel lymph node biopsy tissues and the identification of isolated tumor cells and micro-
metastases that are commonly missed with traditional histopathology. We have demonstrated through our
preliminary studies that using this approach we can identify these cancer cells in tissues that were previously
characterized as node negative and that we can differentiate true negative from false negative samples.
The focus of this project is to take this approach and transform it into a CLIA diagnostic assay that can be
offered as a laboratory developed test to patients with negative sentinel lymph node biopsies at the conclusion
of this Phase II work. Initially, the test will be offered following traditional tissue evaluation but eventually could
be used as a primary diagnostic approach for all melanoma sentinel lymph node biopsy tissues. The
development of this assay will be completed through conducting a retrospective clinical study in partnership
with Cedars-Sinai with archived negative sentinel lymph node biopsy tissue blocks where the approach will be
used to characterize these samples in their entirety. Through this study, we will demonstrate the accuracy,
specificity and sensitivity of the test and will be able to quantify the extent to which it reduces the incidence of
false negatives in the characterization of sentinel lymph node biopsies. Through the execution of this clinical
study, we will build a statistical model that will threshold samples based upon their underlying three-
dimensional features (e.g. total number of cancer cells, cancer cell aggregate volume, density of cancer cells)
and classify them as ‘no metastases present’ (i.e. true negative) or ‘metastases present’ (i.e. true positive).
Furthermore, the software we develop will for positive samples describe where a section should be taken from
the sample for confirmation by a Visikol pathologist using traditional histopathology such that the report from
the assay fits into the traditional classification paradigm. Lastly, we will transform our digital pathology software
analysis approach into a 21 CFR part 11 compliant application which will be required at the conclusion of the
project to start offering the assay as a CLIA test. To support this approach and to allow for the launch of a
laboratory developed test, we will also build the validation documentation package and associated tests
required to demonstrate the range, specificity, reproducibility, accuracy and precision of the assay. Therefore,
at the conclusion of this project we will have built and validated an assay which can start to be offered to
patients following the build-out of a CLIA lab and staffing with clinical personnel.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government